Not a company — an individual defendant. "Xavier Becerra" in this database is a person, not a corporate entity: Xavier Becerra (b. 1958, Sacramento, California), a U.S. lawyer and public official. He served as the 25th U.S. Secretary of Health and Human Services (HHS) from March 2021 to January 2025 under President Biden — the first Latino to hold the office — after serving as California Attorney General (2017–2021) and 12 terms in the U.S. House of Representatives. Since leaving HHS he has been a candidate in California's 2026 gubernatorial race. Ownership status, revenue, and ticker are not applicable; he is a government officeholder.
"Operations." In the tracked case he is named solely in his official capacity as HHS Secretary, the office that administers the federal health apparatus: the FDA, CDC, NIH, and CMS, including Medicare, Medicaid, ACA marketplaces, and drug-price negotiation. HHS is the largest federal agency by budget (roughly $1.7 trillion), and Becerra was described in Senate confirmation proceedings as leading it accordingly. He personally manufactures or sells nothing.
Litigation posture. The structured data show 0 cases as plaintiff and 1 as defendant, which is consistent with a public official sued over agency action rather than a patent plaintiff. The sole tracked matter is Avadel CNS Pharmaceuticals, LLC v. Xavier Becerra et al., No. 1:22-cv-02159 (D.D.C., filed July 21, 2022), naming Becerra, HHS, the FDA, and FDA Commissioner Robert Califf. It was an Administrative Procedure Act challenge to an FDA patent-certification decision, not a patent infringement suit. The D.C. district is the default venue for challenges to federal agency action — not a plaintiff-friendly patent venue like the Eastern District of Texas.
Notable context. Avadel sought to compel final approval of LUMRYZ (sodium oxybate) for narcolepsy while a Jazz Pharmaceuticals REMS method-of-use patent ('963) sat in the Orange Book; Judge Amit Mehta granted summary judgment to the federal defendants, directing Avadel to the parallel Delaware patent litigation. A related follow-on, Jazz Pharmaceuticals, Inc. v. Becerra (No. 1:23-cv-01819, D.D.C., 2023), challenged FDA's approval of LUMRYZ over Xywav orphan-drug exclusivity.